Science Exchange Honored by Goldman Sachs for Entrepreneurship

October 19, 2017 | Posted by Team in Company, Events, Press Release, Science Exchange News |

Co-Founder and CEO Elizabeth Iorns Among 100 Most Intriguing Entrepreneurs at 2017 Builders + Innovators Summit

Palo Alto, CA – October 19, 2017 – Goldman Sachs (NYSE:GS) is recognizing Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange as one of the 100 Most Intriguing Entrepreneurs of 2017 at its Builders + Innovators Summit in Santa Barbara, California.

Goldman Sachs selected Elizabeth as one of 100 entrepreneurs from multiple industries to be honored at the two-day event.

The life sciences research community has been transformed by Elizabeth’s ability to execute upon her vision to transform the procurement and delivery of outsourced R&D services. Thanks to her tenacity and drive, and her deep understanding of the need for improved R&D efficiency, Science Exchange is enabling breakthrough scientific discoveries by providing researchers with an online platform for efficient access to the world’s best outsourced R&D service providers.

“This is a tremendous honor and I’m excited to be recognized by Goldman Sachs along with these other inspiring entrepreneurs,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “The work our team at Science Exchange has been doing in outsourced R&D is critical for driving scientific breakthroughs and innovation and I’m proud to lead the team in this charge.”

“We are pleased to recognize Elizabeth Iorns as one of the most intriguing entrepreneurs of 2017,” said David M. Solomon, President and Co-Chief Operating Officer at Goldman Sachs. “This is the sixth year that we’ve hosted the Builders + Innovators Summit where emerging business leaders gather to discuss their common interests in building prosperous organizations.”

For more than 145 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the Summit consists of general sessions and clinics led by Goldman Sachs experts, seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Elizabeth Iorns

Elizabeth Iorns, Ph.D., is the CEO and Founder of Science Exchange. Elizabeth Iorns has transformed scientific research by radically improving the procurement and delivery of outsourced research and development (R&D) services. Elizabeth Iorns, Ph.D. (Institute of Cancer Research, London) was an Assistant Professor at University of Miami’s Miller School of Medicine, where she investigated breast cancer development and progression, before launching Science Exchange in 2011. Elizabeth’s work has been featured in multiple media outlets, and she regularly speaks at thought leadership events, such as the 2017 TechCrunch Disrupt event in San Francisco, 2017 Society for Laboratory Automation and Screening annual meeting and the 2016 MassBio CRO/CMO Symposium. Her recent honors include Nature’s “Ten People that Mattered,” WIRED’s “50 Women Who Are Changing The World,” and the “Kauffman Foundation Emerging Entrepreneur Award.” She is a finalist for 2017 Scrip Executive of the Year Award.

About Science Exchange
Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

Service Provider Qualification and Monitoring Processes at Science Exchange

October 9, 2017 | Posted by Team in Company, Outsourcing Best Practices |

R&D organizations are rightfully cautious when selecting service providers. So much is at stake — reputation, intellectual property, pipeline decisions, regulatory approval, financial investments, and time. ISO 9001 Certified QMS Science Exchange

By partnering with Science Exchange, R&D organizations can finally rest assured that they are accessing a network of service providers that meets their most stringent criteria for quality and integrity.

Put your reputation into the best hands.

Every service provider on the Science Exchange platform is rigorously qualified and operates under pre-established legal agreements that protect intellectual property (IP), define confidentiality obligations, and ensure quality and compliance.

We stand by the unmatched quality of our ISO 9001-certified service provider qualification and monitoring processes. Our process verifies details of service provider compliance, reputation, financial standing, and staff expertise:

Provider Qualification & Monitoring Criteria  

Compliance Reputation Financials Expertise & Resources
  • Basic info (contact, billing, shipping)
  • Proof of certifications
  • FDA warning letters
  • USDA violations
  • Anti-bribery/Anti-corruption*
  • Social media
  • Client referrals
  • BBB complaints
  • Website verification
  • Facility/operations photos
  • Tax documents
  • Financial standing
  • Risk assessment
  • Employee headcount
  • Staff bios
  • Instrumentation
  • Detailed service descriptions
  • Validation data
  • Publications/patents

We require submission of compliance and capabilities information to help our clients determine whether the provider is the best fit for a proposed study. Information is either incorporated into the Science Exchange storefront for each facility or is stored within Science Exchange’s database. *Science Exchange checks against FPAC enforcement actions for anti-bribery/anti-corruption compliance.

Request a demo to see how our service provider quality management system protects our partner R&D organizations.

New on Science Exchange: Focus on Spectrometry

October 4, 2017 | Posted by Team in New Innovations, Research |

Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com

This installment of New on Science Exchange features spectrometry experts at CMP Scientific, Protypia, CovalX, Nightingale Health, and The Scripps Center for Metabolomics. Ready.. set … analyze.

Emass-II Ion Source CMP Scientific

CMP Scientific: Capillary electrophoresis – mass spectrometry (CE-MS) experts

Analytical researchers frustrated by the long separation times, high sample requirements, or low throughput of LC-MS have long been attracted to the advantages of CE-MS.

In 2015, the CE-MS technique was revolutionized — in that year, Brooklyn, New York-based CMP Scientific pioneered the EMASS-II CE-MS ion source, a novel interface between the capillary and the mass spectrometer’s electrospray emitter that conferred nanoflow sensitivity and high electrospray efficiency.

Since then, CMP Scientific has gained a proven track record for helping drug discovery and development companies develop CE-MS methods for pharmaceutical and biopharmaceutical analysis. Will your research program be the next to benefit from CE-MS technology?

Connect with the CMP Scientific team on Science Exchange.

 

The Scripps Center for Metabolomics: Respected mass spec core exposes the exposome

What are the biological effects of the exposome — i.e., the sum of all environmental toxicants, food contaminants and supplements, drugs, and antibiotics your body is exposed to daily?

Thanks to XCMS/METLIN, a software combined with a cloud-based database founded by the researchers at the Scripps Center for Mass Spectrometry and Metabolomics, investigations into the elusive exposome are now possible. On September 25, the lab published the results of their initial study — and we were very excited to have such a groundbreaking team join the Science Exchange network!

The facility serves its customers both at Scripps Research Institute as well as in the broader biotechnology community with its analytical expertise, for routine as well as specialty projects. They offer not only ESI, MALDI, and GC/MS of a wide range of samples and analytes, but also access to the world’s leading metabolomics/lipidomics platform.

 

Nightingale Health: Epidemiology-scale metabolomics, using NMR

Based in Helsinki, Finland, Nightingale Health has been transforming population health studies using its novel, NMR spectroscopy-based platform to detect multiple metabolites, across diverse pathways, in human plasma and serum. This fully automated biomarker quantification method can provide superior repeatability compared to mass spectrometry methods and is coupled with automated quality control.

Now available on Science Exchange, Nightingale Health’s services are accessible to researchers seeking novel biomarkers for large population studies of cardiovascular health, diabetes, and other aspects of metabolic syndrome.

 

Protypia: Advancing immunooncology through quantitative proteomics

The complexity of immune checkpoint signaling has led the field to the conclusion that there are more determinants to immunotherapeutic efficacy than PD-1 or PD-L1 expression alone. Vanderbilt University’s Daniel Liebler, President and Founder of Protypia, has used his team’s expertise in quantitative proteomics to show that differential glycation of checkpoint signaling proteins could affect tissue staining results as well as signaling protein function [abstract].

Visit the Protypia storefront to request a quote for your proteomics project — this team might just enable your next drug discovery breakthrough.

 

CovalX: High-Mass MALDI yields cost-effective info on epitopes

Founded in 2005, this global, fast-growing service provider established its prominence by developing a very differentiated technology  — fast, sensitive and accurate analysis of protein complexes by High-Mass MALDI mass spectrometry. Unfragmented and undigested, the protein complexes are detected intact using specially developed cross-linking reagents and high-mass detection system.

Combined with CovalX’s covalent crosslinking technology, this mass spectrometry method provides a method for epitope mapping that is faster and more cost-effective than many other conformational analysis techniques. For researchers analyzing protein biotherapeutics and biosimilars, it’s an attractive option.

 

Browse these and other new service providers on Science Exchange today!

 

Easing the Bioinformatics Bottleneck: OnRamp Bioinformatics

October 4, 2017 | Posted by Team in Helpful products, Lab Profiles, New Innovations, Research, Uncategorized |

By Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.comOnRamp Bio Logo

According to Tim Wesselman, CEO of today’s featured provider OnRamp Bioinformatics, there are only 15,000 bioinformaticians worldwide today to support more than 2 million biologists and other researchers. As a result, analysis has become the rate-limiting step in next-generation sequencing studies, and very large datasets may go un-analyzed to the point of obsoletion.

To ease this bottleneck, OnRamp Bio offers services that empower researchers with insights that they can understand and put into action.

Software as a service: accessible bioinformatics for non-experts

OnRamp Bio has made significant progress in making bioinformatics accessible to larger numbers of researchers. Earlier this year, OnRamp Bio launched a new software-as-a-service for RNA-Seq analysis, to meet the needs of researchers needing assistance in making decisions based on the large data sets yielded by RNA-Seq experiments.

Genomics big data and complex software analyses have historically required highly trained PhDs in Bioinformatics using complicated command-line tools. OnRamp Bio’s intuitive user interface, automated analyses and robust data management make it faster and easier for scientists, biologists, clinicians and other medical professionals to obtain interpretations of genomic data without the complexity of traditional deployments.

“IT complexity has stood in the way of progress for far too long. We’ve combined our deep knowledge of IT and biology to provide intuitive, integrated systems and services that accelerate mainstream adoption of NGS analyses within biotech and pharma,” said Tim Wesselman, CEO of OnRamp Bio. “For institutions focused on drug discovery, cancer research, diagnostic, or therapeutic development, OnRamp Bio can help show how to implement next generation sequencing to securely build into future research, while getting immediate answers more cost-efficiently.”

In addition to offering end-to-end genomic analysis services, OnRamp Bio recently made the news when it launched Rosalind™, the first-ever software platform specifically designed to simplify genomic analysis (named for one of the researchers who discovered the double helix structure of DNA).

Faces of OnRamp Bioinformatics

Jeremy Davis-Turak OnRamp BioJeremy Davis-Turak, VP of Bioinformatics, earned his Ph.D. in Bioinformatics and Systems Biology in the lab of Dr. Alexander Hoffmann at UCSD, researching kinetic models of co-transcriptional splicing.  In his studies, Dr. Davis-Turak developed analyses for RNA-seq, nascent RNA-seq, GRO-seq and MNase-seq that were intimately linked with mechanistic models.  He set up the Bioinformatics Core at the San Diego Center for Systems Biology, optimizing pipeline for RNA-seq and ChIP-seq.  

 

Jean Lozach OnRamp BioJean Lozach, Chief Technology Officer, joined OnRamp Bio after more than 25 years experience in Genomics, Bioinformatics and Information Technology at Illumina and UCSD. Jean brought deep experience and knowledge of biology, wet lab operations, microarrays, and next generation sequencing together with advanced bioinformatics, software development and enterprise IT infrastructure. Jean is recognized as an industry expert in genomics and bioinformatics, and has led tens of successful customer deployments of next generation sequencing and informatics systems.

Roshni Patel OnRamp BioRoshni Patel, Bioinformatician, has helped complete many projects for OnRamp Bio’s clients. She earned her BS of Bioinformatics from the University of California at San Diego, and she is passionate about breaking down workflow complexity, improving data metrics and visualization.

 

 

What Science Exchange Requesters are saying about OnRamp Bioinformatics

OnRamp Bio’s storefront shows several testimonials from Science Exchange requesters. One review, in particular, applauds both the breadth and quality of their services: “I highly recommend OnRamp for their Bioinformatics expertise. I have worked with them on several genomics and metagenomics projects and the team is professional, completes the work on deadline and budget, and generated results we hadn’t expected. OnRamp will work with you every step of the way, from project inception, through interfacing with sequencing partners, through developing novel informatics solutions for your project. OnRamp’s bioinformatics platform has many unique attributes that make it appealing, but their data and analysis tracking is just amazing: provenance for all your analyses from the minute the sequences arrive.”

 

Visit the OnRamp Bio storefront today to request some quotes!

 

Science Exchange Appoints Jim Emerich as Chief Financial Officer

September 29, 2017 | Posted by Team in Company, Press Release, Science Exchange News |

Veteran finance executive Emerich joins Science Exchange to help lead the company through next phase of growth

PALO ALTO, CA, SEPTEMBER 28, 2017 Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), announced today it has appointed Jim Emerich as Chief Financial Officer (CFO).Science Exchange CFO Jim Emerich

In this role, Emerich will provide hands-on, metrics-driven financial leadership to help accelerate growth for the company. He will oversee and lead the budgeting and planning process, monitor and communicate progress of key business and financial objectives, and articulate the key drivers of cost and revenue.

“We are thrilled to welcome Jim to our management team. His track record of successfully navigating businesses through periods of financial growth speaks for itself,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is in a period of rapid expansion, and Jim will play a key role as we take this business to the next level, helping us accelerate our profitability and guide our financial planning.”

Emerich brings more than 25 years of finance and operations experience to Science Exchange, with a history of boosting performance through fiscal analysis and strategy. Most recently, Emerich was the CFO of BrightEdge Technologies Inc. Previously, he served as CFO at Avangate Inc., Appiro Inc., and Mulesoft Inc. In addition, he has held executive finance roles at SalesForce.com, NotifyMe Networks, NBC Internet, Inc., LDM Technologies, Inc., and General Electric Plastics.

“I have been impressed with Science Exchange’s growth trajectory, the breadth of its service provider network, its client roster of the world’s top bio and pharma companies, and the strength of its current financial operations,” said Emerich.  “The company has proven indispensable to both researchers and R&D organizations, helping to drive both efficiency and access to innovation. I look forward to working with the team to help guide Science Exchange through this next phase of growth and development.”

 

New on Science Exchange: ActiveMotif, Optopatch, & CV Tox for World Heart Day

September 20, 2017 | Posted by Team in Drug Discovery, New Innovations, Research |

by Chandreyee Das, Ph.D., Senior Content Manager, Science Exchange | www.scienceexchange.com

We observe World Heart Day at Science Exchange by highlighting a novel technology for assessing cardiac safety, from the Efimov Lab at George Washington University. Other newcomers on our platform that we present to you are ActiveMotif, Oncodesign, QurAlis, and Worldwide Clinical Trials.

ActiveMotif: Time to RIME (Rapid IP-MS of endogenous proteins)

It’s the 20th anniversary of the discovery of chromatin — and researchers can treat their favorite chromatin samples to ActiveMotif’s RIME service (Rapid immunoprecipitation mass spectrometry of endogenous

RIME Method ActiveMotif

RIME service from ActiveMotif includes nuclear isolation, sonication, IP, purification, tryptic digestion, MS, and data analysis

proteins). It is an ideal method for identifying transcriptional cofactors and other associated proteins within multi-protein complexes, and is often performed in parallel with ChIP-seq.

A leading provider of kits and services for studying gene regulation (both genetic and epigenetic), ActiveMotif is no stranger to chromatin. RIME is just one of a comprehensive menu of gene regulation services that ActiveMotif offers through Science Exchange — visit the storefront to browse their capabilities.

 

QurAlis: Harvard team uses Dead Sea microbes in novel assays

Founded in May 2017 by Clifford Woolf, Professor of Neurology and Neurobiology at Harvard Medical School, Kevin Eggan, Professor of Regenerative Biology at Harvard, Kasper Roet, Harvard Research Fellow, and Q-State Biosciences, QurAlis focuses the power of Q-State’s powerful, 100% optical electrophysiology platform on novel, stem cell-derived, disease-in-dish models of ALS.

It’s a Dead Sea microorganism that is the basis of the enabling Q-State technology. QuasAr proteins, derived from this microbe, respond to action potentials and synaptic signals by emitting near-infrared fluorescence. These Optopatch assays thus deliver higher throughput and information content than traditional patch clamp assays, and they also provide better resolution and lower phototoxicity than other optical screening tools.

We’re very excited to have QurAlis join Q-State Biosciences on our network, giving neurobiology researchers easy access to the expertise of the QurAlis team.

 

Worldwide Clinical Trials: Early phase services now available on Science Exchange

In the high-stakes service category of clinical trials, Worldwide stands out. In fact, Worldwide’s Chief Medical and Scientific Officer, Michael F. Murphy, M.D., Ph.D., was recently named one of the PharmaVOICE 100 Most Inspiring People of 2017 — for the impact of Dr. Murphy’s dedication to innovation.

Continuously working to improve trial design and patient outcomes, Worldwide now offers early phase services on the Science Exchange network. Click on the Worldwide storefront to access this major global CRO without needing a separate contract.

 

Efimov Lab: Predictive preclinical models of cardiovascular toxicology

An apt addition to the Science Exchange platform, in time for World Heart Day (September 29!), is the Efimov Laboratory at George Washington University.

Known around the world as a leader in cardiovascular science and biomedical engineering, Dr. Igor Efimov and his team developed a method for optically mapping organotypic cultures of donor human heart slices, enabling users to test the cardiac safety and efficacy of therapeutic candidates.

The culture method preserves heart tissue architecture and extracellular matrix — aspects of heart health that cannot be revealed by iPSC-derived cardiac cells or other traditional assays for cardiovascular toxicology. Visit the lab’s storefront for a list of their recent exciting publications — this is clearly a team to watch.

 

Oncodesign: Preclinical assessment of anti-cancer therapies

True thought leaders in the field of preclinical drug discovery and development, Oncodesign made the news last year when it partnered with Bristol-Myers Squibb to develop novel macrocyclic candidates and test them using their proprietary xenograft models and imaging technology.

Now, Oncodesign’s services are easily accessible to Science Exchange requesters. We get extremely excited thinking that a requester on our platform with a promising therapeutic candidate may now use Oncodesign’s Predict®, Chi-mice®, Pharmimage® and other platforms to characterize their candidate, speeding it along the path to potential cancer patients. Start a conversation with this leading CRO by submitting your Scope of Work here.

 

 

Connect with a new provider today!

Are you new to Science Exchange? See how it works.

The Robotic Cloud Laboratory for the Life Sciences: Transcriptic

September 20, 2017 | Posted by Team in Drug Discovery, Lab Profiles, New Innovations, Research |

Transcriptic LogoBy Natalie Foote, Director of Service Provider Operations, Science Exchange | www.scienceexchange.com

 

In this Provider Innovation Profile, we’re proud to feature Transcriptic, whose automated cellular and molecular biology platform enables scalable life science research with flexibility and precision.

Automation is a rapidly advancing area of biotechnology, and Science Exchange hopes to give our researchers access to unique robotics platforms while helping them save on equipment costs and manage laboratory space limitations.

Transcriptic’s robotic cloud lab paradigm means biologists can be running experiments on the other side of the planet from their lab, leveraging a bank of robotic workcells for massive experimentation.

Transcriptic frees researchers to focus on the creative aspects of their science by providing faster, more reliable and repeatable processes with vastly lower capital costs than previously possible.

Differentiators: Transparency, flexibility, multiplex-ity

Transcriptic Robotic Workcell

Multiple integrated automated devices per workcell

  • Transparency: No other service provider on the planet can tell you exactly how they run an experiment on the user’s behalf. Transcriptic provides deep transparency into how users’ experiments were run by executing experiments exactly as specified and also providing retrospective diagnostic data on individual instrument performance during the experiment.
  • Flexible robotics: Being a robotic cloud lab, the Transcriptic system can dynamically provision robotic resources to process samples for users. For example, the system might start the week at a scale of one plate and end the week on hundreds of plates. Users only pay for the resources they use, reaping the reproducibility and throughput benefits of robotics without any of the overhead.
  • Easy multiplexing: The Transcriptic web application makes it easy as checking a box to detect an additional analyte in your sample. When it’s that easy, you can perform multiplexed quantiation of more analytes, starting to generate a more accurate picture of the phenotypic state of your sample.

Featured Service: Mesocale Discovery (MSD) Assay

The MSD assay, validated in many bioanalytical methods per U.S. FDA and EMA guidances, is offered as a service by Transcriptic. The Mesoscale Discovery Sector S 600 instrument is fully integrated with the Transcriptic robotic cloud lab.

The MSD S 600 instrument performs multiplexed detection of up to 10 analytes per well, ensuring the highest data-to-sample quantity efficiency, in immunoassays. Multiple assay panels are available from the V-Plex line, all conducted with complete automated precision by robots in the cloud. Custom panel assays are also available through the MSD U-Plex system.

Why requesters choose Transcriptic

Transcriptic, in collaboration with multiple biopharma companies and non-academic laboratories, has delivered many peer-reviewed publications and conference presentations.

Transcriptic presented one interesting study at SynBioBeta 2016. In collaboration with EpiBiome, Transcriptic’s automated platform provided a robust, reproducible and high-throughput method for on-demand microbiome characterization. This workflow captured sample prep through NGS and sequencing analysis in 7-10 days, allowing for fast, iterative cycles of microbiome screening.

Visit the Transcriptic storefront today to request some quotes!

 

Science Exchange Survey Reveals Pain Points of Outsourcing R&D

September 18, 2017 | Posted by Team in Company, Outsourcing Best Practices, Press Release |

Contract review, service provider qualification, and security of intellectual property among major concerns for biotech and pharma leaders surveyed at 2017 industry conferences

PALO ALTO, Calif.– More than 100 biotechnology and drug development leaders who responded to surveys conducted during industry conferences earlier this year reported a wide range of barriers to the outsourcing of research and development (R&D) services, including the contracts review process, intellectual property (IP) security concerns, and service provider qualification. The surveys were conducted by Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), during the 2017 Biotechnology Innovation Organization (BIO) International Convention and 2017 Drug Industry Association (DIA) Global Annual Meeting.

More than 75 percent of Science Exchange survey respondents ranked the following concerns as barriers (a significant barrier or somewhat of a barrier) to the outsourcing of R&D services:

  • Having contracts reviewed and signed
  • Security of IP;
  • Identifying service providers with required expertise;
  • Qualifying service providers; and
  • Negotiating pricing.

Time management related to R&D outsourcing was also reported as having a significant impact on these R&D leaders, with over 40 percent of those responding to the survey indicating they spent more than 20 hours to onboard each new outsourcing partner, from the request for proposal process, through contracting and start of the project. Finally, further demonstrating the impact of the time spent on administrative tasks related to outsourcing, more than 75 percent of survey respondents reported that the “hassle” of bringing on a new partner has previously led them to choose an existing vendor rather than seek out a more qualified option.

“The results of this survey echo the same concerns we heard from the leading biotech and pharma companies who now rely on Science Exchange to help them efficiently manage their outsourced R&D services,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “In review of enterprise clients’ experiences, we find that our Science Exchange clients save thousands of work hours each year on procurement, business operations, contracting and legal resources, and administrative tasks related to outsourcing — time that can instead be spent in discovery. It’s gratifying to see that we’re able to fulfill our goal to support the scientific discovery process by removing barriers to innovation for our clients.”

See how your organization could streamline outsourced R&D through Science Exchange — request a demo of our platforms for enterprise clients.

Science Exchange Releases Latest Version of its Enterprise Dynamic Report Tool

September 11, 2017 | Posted by Team in Company, New Feature, Outsourcing Best Practices, Press Release, Science Exchange News |

Latest release gives enterprise clients access to real-time data to improve reporting and decision-making for outsourced R&D investments

Dynamic Report Tool

PALO ALTO CA, Sept. 11, 2017 – Demonstrating the company’s commitment to support its clients’ growth plans by optimizing data aggregation and business intelligence, Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), recently released the latest version of its enterprise dynamic report tool. The tool enables Science Exchange’s enterprise clients, including some of the world’s top pharma and biotech companies, to perform real-time tracking of key performance indicators (KPIs) related to their outsourced R&D investments.

“The Science Exchange enterprise dynamic report gives me the ability to tease out diverse suppliers and export spend data. Our procurement management team has been thrilled with the report,” said Gregory Smith, Associate Director, Indirect R&D Procurement, Teva Pharmaceuticals Industries, Ltd.

This latest enterprise dynamic report update allows enterprise clients like Teva Pharmaceuticals Industries, Ltd., to:

  • Track spend, budget performance, and outsourcing efficiency in real time;
  • Gain visibility into service provider performance metrics; and
  • Better assess efficiency of outsourced R&D programs.

“With this dynamic reporting tool, our enterprise clients are able to gain a whole new understanding of category-specific purchasing behaviors within their organizations. R&D and procurement leaders can receive and proactively analyze – in real time – data and business intelligence that can help them quickly assess the performance and impact of their outsourced R&D programs, ” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange helps our clients make data-driven business decisions, while at the same time giving researchers quick and secure access to more than 2,500 scientific service providers – allowing researchers to focus on innovation and discovery.”

Learn more about enterprise partnerships with Science Exchange, and request a demo of our private marketplaces for outsourced R&D:
www.scienceexchange.com/enterprise

 

Science Exchange Signs on as LabCentral Sponsor to Support Life Science Startups with Outsourced Services

August 30, 2017 | Posted by Team in Company, Press Release, Science Exchange News, Small Biotech Stories |

LabCentral Partners with Science Exchange

Cambridge-based LabCentral’s high-potential startups will now have access to the Science Exchange network of more than 2,500 qualified scientific service providers

PALO ALTO, Calif. and CAMBRIDGE, Mass. (August 30, 2017) – Biotech innovation hub LabCentral today announced that it has signed Science Exchange, the world’s leading and most secure platform for outsourced research and development (R&D), as a sponsor to support its life science and biotech resident startups. Companies within LabCentral’s shared workspaces are now able to order R&D services instantly via a customized Science Exchanged-powered marketplace, with access to more than 2,500 qualified scientific service providers.

“We’ve designed LabCentral as a supportive and nurturing environment designed to inspire interaction and collaboration, providing everything that early-stage companies need to thrive, moving their science forward faster, and cost-effectively,” said LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D. , LabCentral. “We’re thrilled to have Science Exchange support our companies by offering instant access to their network of innovative service providers — it’s another way we can provide our startups the resources they need to accelerate their groundbreaking discoveries.”

LabCentral joins more than 30 enterprise clients that are using Science Exchange-powered marketplaces to manage their outsourced R&D. This partnership addresses the needs of LabCentral’s unique ecosystem, giving its startup network the same level of access to advanced scientific services that is enjoyed by Science Exchange’s established global pharmaceutical and biotechnology clients. With these new resources, early-stage companies will be able to continue to drive their discoveries forward.

A biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launch-pad for high-potential life science and biotech startups. It offers fully permitted laboratory and office space for dozens of startups. LabCentral provides facility and administrative support, skilled laboratory personnel, and other critical services and support that early-stage companies need to begin laboratory operations on day one.

“The opportunity to partner with organizations like LabCentral is why we founded Science Exchange six years ago,” said Dr. Elizabeth Iorns, founder and CEO of Science Exchange. “We deliver efficient and secure access to thousands of qualified scientific service providers – removing significant barriers to innovation and helping companies bring important products to market faster.”

The Science Exchange marketplace will help LabCentral’s resident companies:

  • Gain immediate access to qualified service providers. Science Exchange offers a network of more than 2,500 service providers that have been qualified through a stringent, ISO 9001-certified evaluation process that includes metrics tied to performance on past projects.
  • Reduce administrative and regulatory review costs. Under the partnership, all service providers on the LabCentral-Science Exchange network are available under a single contract that protects intellectual property and confidentiality. Science Exchange’s in-house audit team also conducts inspections to ensure that contracted service providers possess necessary certifications, licenses, informed consent of subjects, and data security.
  • Save time and money. The LabCentral entrepreneurs and startups working on groundbreaking scientific discoveries will now be able to quickly request competitive bids through the Science Exchange platform and select the right partner to keep their projects on track. 

About LabCentral (www.labcentral.org; twitter @labcentral)

LabCentral is a first-of-its-kind shared laboratory workspace in the heart of the Kendall Square, Cambridge, biotech innovation hub. Designed as a launchpad for high-potential life-sciences and biotech startups, it offers everything startups need to begin laboratory operations on day one and move their science forward faster and more cost-efficiently. This includes: fully permitted laboratory and office space, first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support. A private, nonprofit institution, LabCentral’s first site opened in 2013, thanks to a capital grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation.

 

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com